Drug news

Encenicline (FRM 6124) fails in two Phase III trials to treat cognitive impairment with schizophrenia- Forum Pharma

Read time: 1 mins

Last updated:29th Mar 2016

Published:29th Mar 2016

Source: Pharmawand

Topline results were announced by Forum Pharma of two Phase III trials in patients with cognitive impairment with schizophrenia and they demonstrated for encenicline (FRM 6124) a favourable safety and tolerability profile but neither study met its co primary endpoint based on cognitive function and patient function. An unexpected placebo response was observed in both trials.The Company will implement significant restructuring.

Comment: The FDA still has the Alzheimer's program for encenicline on hold after a number of patients taking the drug reported severe gastrointestinal events last year.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Ojemda (tovorafenib) receives FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG), the most common form of childhood brain tumor

Day One Biopharmaceuticals, Inc , announced that the FDA has approved Ojemda (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory BRAF-altered pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

4 mins

Drug news

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria.

Novartis and Medicines for Malaria Venture (MMV) announce positive data from their phase II/III CALINA study, demonstrating that a novel formulation of Coartem (artemether-lumefantrine) developed for babies weighing less than 5kg with malaria has the required pharmacokinetic profile and good efficacy and safety

3 min

Drug news

European Commission approves Emblaveo (aztreonam-avibactam) for patients with multidrug-resistant infections and limited treatment options

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Emblaveo (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis

1 min

See all news